Skip to content

Safety evaluation and effect of consumption of pineapple byproduct as cider to reduce the risk of metabolic disorders

Safety evaluation and effect of consumption of pineapple byproduct as cider to reduce the risk of metabolic disorders

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
TCTR
Registry ID
TCTR20210616007
Enrollment
75
Registered
2021-06-16
Start date
2021-07-29
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy conditions Pineapple cider vinegar metabolic disorders lipid profiles

Interventions

Subjects are received the placebo product which has the same color and smells look like a pineapple cider beverage.,Subjects are received pineapple cider beverage 15 ml/day for 8 weeks.,Subjects are r
Placebo,Pineapple cider beverage 15 ml/day,Pineapple cider beverage 30 ml/day

Sponsors

National Research Council of Thailand (NRCT)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Aged between 35-60 years old 2. Body Mass Index (BMI) more than 23 kg/m2

Exclusion criteria

Exclusion criteria: 1. Volunteers who have been diagnosed with one of the following; cardiovascular diseases, respiratory diseases, neuropsychological diseases, liver disease (AST more than 64 U/L, ALT more than 50 U/L), Kidney disease (estimate GFR less than 90 ml/min), autoimmune disease, hematological disorder, and cancer 2. Volunteers who require supplements or any drug that affect the nervous system by order of the doctor before trial 3. Volunteers who use supplements or any drug that affect the body weight, glucose, and lipid level before trial 4. Smoking more than 10 pieces/ day 5. Drinking alcohol more than 5 times/ day 6. Volunteers who participate in other projects 7. Pregnancy or lactating women 8. Blood pressure less than 140/90 mm Hg and Fasting Blood Sugar (FBS) after fasts for 8 hours less than 126 mg/dL

Design outcomes

Primary

MeasureTime frame
Metabolic parameters include Homeostasis Model Assessment Insulin Resistance (HOMA-IR) index, Atherosclerosis index (AI Index) , Atherogenic index of plasma (AIP), and Insulin 8 weeks Laboratory

Secondary

MeasureTime frame
The changes of hematological and clinical chemistry parameters 8 weeks Laboratory,Oxidative stress markers include Malondialdehyde (MDA), Superoxide dismutase (SOD), Catalase (CAT), and Glutathione peroxidase (GSH-Px) 8 weeks Laboratory,Angiotensin converting enzyme (ACE) 8 weeks Elisa method,Advanced glycation end products (AGEs) 8 weeks Elisa method,Urinalysis 8 weeks Laboratory, Homocysteine 8 weeks Laboratory,Body Composition, Body Mass Index (BMI), and Anthropometry 8 weeks Equipment,The changes of electrocardiogram 8 weeks Electrocardiography

Countries

Thailand

Contacts

Public ContactPanakaporn Wannanon

Khon Kaen University

wpanak@kku.ac.th0815460940

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026